$HYMC
Should be adding here on the 200 MA...
But.... does this gap on the weekly bother anyone else?
You know deep down in your spleen that it just wants to wick back in there on a market panic.
Can this pharma lift the 'World Cup and Handle?'
Rare disease play with potential large upside.
Strong revenue growth with profitability turnaround.
Solid balance sheet and promising product pipeline.
GOAL or RED CARD? Time will soon tell.
Can this pharma lift the 'World Cup and Handle?'
Rare disease play with potential large upside.
Strong revenue growth with profitability turnaround.
Solid balance sheet and promising product pipeline.
GOAL or RED CARD? Time will soon tell.
Can this pharma lift the 'World Cup and Handle?'
Rare disease play with potential large upside.
Strong revenue growth with profitability turnaround.
Solid balance sheet and promising product pipeline.
GOAL or RED CARD? Time will soon tell.
@weebabalu Uranium and Critical Minerals... Got a vibe that a bid is coming after this sector-wide grind down. May need to pull back a tad more to break the last hands who are poorly positioned.
$UUUU is on my watch list as it ticks both boxes. Along with $AREC for critical minerals.
@JaguarAnalytics Do we need to be concerned at all with the Korean currency collapse and their concurrent parabolic stock market melt up? Would be keen to hear what the panel thinks. ✌️
🚨 $MSTR HIGH CONVICTION INSIDER SELL
- Actor: Patten Jarrod M (Director)
- Volume: 22,300
- Holdings Impact: 100.0% of total position
- Historical Win Rate: 33%
- 10b5-1 Plan: No
- Average Price: $152.60
- Gross Proceeds: $3,402,892.50
- Liquidity Impact: 0.14% of 30-day ADTV
CONVICTION SCORE: 4/10
MARKET THESIS:
Director Patten Jarrod M has liquidated his entire equity stake in MSTR outside of a 10b5-1 plan, signaling a total exit from the position. While the firm recently broke its multi-year Bitcoin holding strategy to fund preferred stock dividends—a move that triggered market volatility and a $15M Polymarket dispute—this insider sale lacks the predictive weight of a high-alpha signal. Given the director's poor historical win rate of 33% and an average post-trade outcome of -20.4%, this liquidation is likely a personal liquidity event rather than a reflection of institutional confidence in the firm's pivot to dividend funding.
🤖 AI-Curated Data Pipeline | Not Financial Advice